Predictive Accounts Payable from 2010 to 2025

POAI Stock  USD 0.78  0.01  1.27%   
Predictive Oncology's Accounts Payable is increasing with stable movements from year to year. Accounts Payable is predicted to flatten to about 1.1 M. Accounts Payable is the amount Predictive Oncology owes to suppliers or vendors for products or services received but not yet paid for. It represents Predictive Oncology's short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2008-12-31
Previous Quarter
1.1 M
Current Value
1.2 M
Quarterly Volatility
806.3 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Predictive Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Predictive Oncology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 415.4 K, Interest Expense of 12.9 M or Selling General Administrative of 7.1 M, as well as many indicators such as Price To Sales Ratio of 2.62, Dividend Yield of 0.0 or Days Sales Outstanding of 91.54. Predictive financial statements analysis is a perfect complement when working with Predictive Oncology Valuation or Volatility modules.
  
Build AI portfolio with Predictive Stock
Check out the analysis of Predictive Oncology Correlation against competitors.
For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.

Latest Predictive Oncology's Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Predictive Oncology over the last few years. An accounting item on the balance sheet that represents Predictive Oncology obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Predictive Oncology are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Predictive Oncology's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Predictive Oncology's overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Pretty Stable
   Accounts Payable   
       Timeline  

Predictive Accounts Payable Regression Statistics

Arithmetic Mean1,048,021
Geometric Mean817,472
Coefficient Of Variation71.85
Mean Deviation506,051
Median1,021,774
Standard Deviation753,040
Sample Variance567.1B
Range3M
R-Value0.23
Mean Square Error575.4B
R-Squared0.05
Significance0.39
Slope36,413
Total Sum of Squares8.5T

Predictive Accounts Payable History

20251.1 M
20241.1 M
20231.3 M
2022943.5 K
2021M
20201.4 M
20193.2 M

About Predictive Oncology Financial Statements

Investors use fundamental indicators, such as Predictive Oncology's Accounts Payable, to determine how well the company is positioned to perform in the future. Although Predictive Oncology's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Accounts Payable1.1 M1.1 M

Currently Active Assets on Macroaxis

When determining whether Predictive Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Predictive Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Predictive Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Predictive Oncology Stock:
Check out the analysis of Predictive Oncology Correlation against competitors.
For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.43)
Revenue Per Share
0.278
Quarterly Revenue Growth
21.707
Return On Assets
(0.73)
Return On Equity
(4.90)
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.